Bendamustine in Chinese Participants With Non-Hodgkin Lymphoma

Study Title
Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
Teva Identifier
C18083/3076
ClinicalTrials.gov Identifier
NCT01596621
Study Status
Completed
Trial Condition(s)
Non-Hodgkin Lymphoma
Interventions
Drug: Bendamustine hydrochloride

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years and older
Trial Duration
August 6, 2012 - April 28, 2017
Phase
Phase 3

Study Type

Interventional